Xlife Sciences AGXSWX:XLS 53 Return-on-Tangible-Equity is -98.65% as of Dec. 2025. GuruFocus rates XSWX:XLS with a GF Score™ of 53/100 and a GF Value™ of CHF7.29 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 1,202 Biotechnology companies, Xlife Sciences AG ranks worse than 58.4% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Xlife Sciences AG's annualized net income for the quarter that ended in Dec. 2025 was CHF-36.99 Mil. Xlife Sciences AG's average shareholder tangible equity for the quarter that ended in Dec. 2025 was CHF37.50 Mil. Therefore, Xlife Sciences AG's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was -98.65%.
The historical rank and industry rank for Xlife Sciences AG's Return-on-Tangible-Equity or its related term are showing as below:
XSWX:XLS'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -62.54 Med: 18.88 Max: 435.35
Current: -58.2
During the past 8 years, Xlife Sciences AG's highest Return-on-Tangible-Equity was 435.35%. The lowest was -62.54%. And the median was 18.88%.
XSWX:XLS's Return-on-Tangible-Equity is ranked worse than 58.4% of 1202
companies
in the Biotechnology industry
Industry Median: -42.435
vs XSWX:XLS: -58.20
Xlife Sciences AG (XSWX:XLS) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Xlife Sciences AG Return-on-Tangible-Equity Related Terms
Xlife Sciences AG Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Xlife Sciences AG's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:XLS vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Xlife Sciences AG's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xlife Sciences AG Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xlife Sciences AG's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Xlife Sciences AG's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -98.65% mean?
Xlife Sciences AG (XSWX:XLS) has a Return-on-Tangible-Equity of -98.65% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Xlife Sciences AG and its competitors. According to the industry distribution chart, Xlife Sciences AG ranks #702 out of 1202 companies in the Biotechnology industry, placing it in the top 58.4%.
Is Xlife Sciences AG's Return-on-Tangible-Equity too high?
Xlife Sciences AG's current Return-on-Tangible-Equity is -98.65%. Based on the distribution chart, Xlife Sciences AG ranks #702 out of 1202 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Xlife Sciences AG has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xlife Sciences AG's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Xlife Sciences AG ranks #702 out of 1202 companies for Return-on-Tangible-Equity. This places Xlife Sciences AG in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Xlife Sciences AG and its competitors. Xlife Sciences AG's current Return-on-Tangible-Equity is -98.65%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xlife Sciences AG stock overvalued right now?
Based on GuruFocus' analysis, Xlife Sciences AG (XSWX:XLS) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF7.29, compared to a current price of CHF20.20 — trading 177.1% above its estimated fair value. The current Return-on-Tangible-Equity is -98.65%. Xlife Sciences AG's overall GF Score™ is 53/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Xlife Sciences AG (XSWX:XLS), the current Return-on-Tangible-Equity is -98.65% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xlife Sciences AG (XSWX:XLS) Overvalued in 2026?
Based on GuruFocus' analysis, Xlife Sciences AG stock appears to be overvalued.
The current stock price of CHF20.20 is trading 177.1% above its estimated GF Value™ of CHF7.29.
GuruFocus considers Xlife Sciences AG to be Significantly Overvalued.
Key valuation signals for XSWX:XLS:
Return-on-Tangible-Equity: -98.65%
GF Value™: CHF7.29 vs. price of CHF20.20 (177.1% above fair value)
No single metric tells the full story. See the XSWX:XLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
53GF Score
Get the complete analysis for XSWX:XLS
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:XLS has been successfully added to your 
